US Patent

US10000480 — Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses

Composition of Matter · Assigned to Bristol Myers Squibb Co · Expires 2033-11-07 · 7y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23, and/or IFN alpha responses.

USPTO Abstract

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Drugs covered by this patent

Patent Metadata

Patent number
US10000480
Jurisdiction
US
Classification
Composition of Matter
Expires
2033-11-07
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.